London: BTG PLC (LON:BTG) Stock Has Just Had Its Buy Rating Reiterated by Deutsche Bank. Shares now Have a GBX 755.00 Target


BTG PLC (LON:BTG) Rating Reaffirmed

The firm has just set a target of GBX 755.00 on BTG PLC (LON:BTG) shares. This is 17.78% from the close price. In analysts report distributed to Clients on Tuesday, 15 December, Deutsche Bank reaffirmed their Buy rating on shares of BTG.

From a total of 6 analysts covering BTG PLC (LON:BTG) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 67% of the ratings are positive. The highest target price is GBX 1100 while the lowest target price is GBX 550. The mean of all analyst targets is GBX 771 with a 20.28% above today’s (GBX 641) stock price. BTG PLC was the topic of 29 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. JP Morgan maintained shares on December 15 with “Overweight” rating. JP Morgan maintained shares with “Overweight” rating and GBX 900 target share price in a report from a November 17. Stifel Nicolaus maintained BTG stock in a recent report from December 14 with “Hold” rating. Stifel Nicolaus maintained the rating on October 6. Stifel Nicolaus has a “Sell” rating and a GBX 550 price target on shares. Finally, Panmure Gordon maintained the stock with “Buy” rating in a report issued on a November 10.

Approximately 18,724 shares of stock traded hands. BTG plc (LON:BTG) has declined 20.37% since May 18, 2015 and is downtrending. It has underperformed by 16.69% the S&P500.

London: BTG PLC (LON:BTG) Stock Has Just Had Its Buy Rating Reiterated by Deutsche Bank. Shares now Have a GBX 755.00 Target

BTG plc is a specialist healthcare company. The company has a market cap of 2.45 billion GBP. The Firm operates in three business divisions: Interventional Medicine (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). It has 54.7 P/E ratio. The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.

According to Zacks Investment Research, “B2Gold Corp. is involved in the exploration and development of gold. The company’s assets are situated in Nicaragua, Colombia, Namibia and Uruguay. B2Gold Corp. is headquartered in Vancouver, Canada.”